(Press-News.org) DURHAM, N.C. -- A seven-year quest to understand how breast cancer cells resist treatment with the targeted therapy lapatinib has revealed a previously unknown molecular network that regulates cell death. The discovery provides new avenues to overcome drug resistance, according to researchers at Duke Cancer Institute.
"We've revealed multiple new signaling pathways that regulate cell death," said Sally Kornbluth, PhD, vice dean of Basic Science and professor of Pharmacology and Cancer Biology at Duke University School of Medicine. "And we've shown, at least in one disease, these signaling pathways can go awry in drug resistance. It also suggests you could manipulate these other pathways to overcome drug resistance."
The researchers -- co-directed by Kornbluth and Neil Spector, M.D., associate professor of medicine at Duke -- identified a protein that effectively shuts down the signals that tell a cell to die, enabling cancer cells to keep growing. That protein, MDM2, is already generating intense interest in the cancer research community because it is a master regulator of the tumor suppressor protein called p53.
Findings are published in the May 7, 2013, issue of the journal Science Signaling.
The Duke research team, with assistance from collaborators at the University of Michigan, identified a new role for MDM2 in activating cell death pathways independent of its role in regulating p53, a known initiator of cell death. More than half of all human tumors contain a mutation or deletion of the gene that controls p53.
The researchers began by studying four different types of breast cancer cells that were able to keep growing despite treatment with lapatinib, a powerful drug that targets two growth pathways commonly disrupted in breast cancer, HER2 and epidermal growth factor receptor. They found that in each case, the drug resistance could be traced to the presence of high levels of MDM2, which was found to be blocking cell death signals independent of whether p53 was activated.
"These results suggest that inhibition of MDM2, at least in the setting of breast cancer, might overcome lapatinib resistance even if p53 is mutated," Kornbluth said.
Spector and his colleagues first reported the activation of estrogen receptor signaling, which led to FDA-approval of lapatinib in combination with letrozole as a first-line treatment for advanced-stage HER2-positive and estrogen receptor-positive breast cancers. Researchers at Duke, including the Spector laboratory, and other investigators have worked to identify various mechanisms of lapatinib resistance.
"The importance of this new MDM2 finding is that it may underlie these proposed mechanisms of resistance and therefore provide a more effective treatment," Spector said.
The findings also suggest that other drugs targeting tyrosine kinases may be vulnerable to resistance using this same mechanism. Gefitinib is a targeted cancer therapy that blocks a tyrosine kinase enzyme to treat non-small cell lung cancers caused by mutations in the epidermal growth factor receptor.
"This study raises the possibility that resistance to other tyrosine kinase inhibitor drugs, such as gefitinib-resistant lung cancer, could involve MDM2," Kornbluth said. "We are now going to investigate whether MDM2 has anything to do with gefitinib resistance."
The lead author of the paper, Manabu Kurokawa, is now an assistant professor at Dartmouth University. Other authors of the paper include Jiyeon Kim, Joseph Geradts, Kenkyo Mastuura, Wenle Xia, Thomas J. Ribar, Ricardo Henao, Neil L. Spector, Mark W. Dewhirst, and Joseph E. Lucas of Duke; Wun-Jae Kim of Chungbuk National University Hospital; and Shaomeng Wang, Liu Liu, and Xu Ran of the University of Michigan.
The study was funded in part by the National Institutes of Health (R01 CA102707) and the National Cancer Institute (K99 CA140948). The Susan G. Komen for the Cure foundation has provided research support into lapatinib resistance. A full list of funders is provided in the published manuscript.
The authors have filed a patent application based on this work. Shaomeng Wang owns stocks and is a consultant for Ascenta, and is a co-inventor on MI-219 and related MDM2 inhibitors. Ascenta has licensed MI-219 and related MDM2 inhibitors from the University of Michigan to Sanofi for clinical development.
###
END
Scientists at the Virginia Tech Carilion Research Institute have discovered how the predominant class of Alzheimer's pharmaceuticals might sharpen the brain's performance
One factor even more important than the size of a television screen is the quality of the signal it displays. Having a life-sized projection of Harry Potter dodging a Bludger in a Quidditch match is of little use if the details are lost to pixilation.
The importance of transmitting clear signals, however, is not relegated to the airwaves. The same creed applies to the electrical impulses navigating ...
A new robotic sensor deployed by Woods Hole Oceanographic Institution (WHOI) in Gulf of Maine coastal waters may transform the way red tides or harmful algal blooms (HABs) are monitored and managed in New England. The instrument was launched at the end of last month, and a second such system will be deployed later this spring.
The results will add critical data to weekly real-time forecasts of New England red tide this year distributed to more than 150 coastal resource and fisheries managers in six states as well as federal agencies such as NOAA, the FDA and the EPA. ...
GAINESVILLE, Fla. — The University of Florida today unveiled the state's most powerful supercomputer, a machine that will help researchers find life-saving drugs, make decades-long weather forecasts and improve armor for troops.
The HiPerGator supercomputer and recent tenfold increase in the size of the university's data pipeline make UF one of the nation's leading public universities in research computing.
"If we expect our researchers to be at the forefront of their fields, we need to make sure they have the most powerful tools available to science, and HiPerGator ...
LA JOLLA, CA---Scientists at the Salk Institute for Biological Studies have identified a protein that drives the formation of pituitary tumors in Cushing's disease, a development that may give clinicians a therapeutic target to treat this potentially life-threatening disorder.
The protein, called TR4 (testicular orphan nuclear receptor 4), is one of the human body's 48 nuclear receptors, a class of proteins found in cells that are responsible for sensing hormones and, in response, regulating the expression of specific genes. Using a genome scan, the Salk team discovered ...
DARIEN, IL – A new study suggests that your level of sleepiness or alertness during the day may be related to the type of food that you eat.
Results show that higher fat consumption was associated with increased objective daytime sleepiness, while higher carbohydrate intake was associated with increased alertness. There was no relationship between protein consumption and sleepiness or alertness. These findings were independent of the subjects' gender, age, and body mass index as well as the total amount of sleep they were getting and their total caloric intake.
"Increased ...
DARIEN, IL – A new study suggests that regularity of bedtime prior to initiation of continuous positive airway pressure (CPAP) therapy is an important factor that may influence treatment compliance in adults with obstructive sleep apnea (OSA).
Results show that bedtime variability was a significant predictor of CPAP adherence, which was defined as four or more hours of treatment use per night. The odds of one-month CPAP non-adherence were 3.7 times greater for every one unit increase in habitual, or pre-treatment, bedtime variability.
"Long-term use of CPAP, such as ...
This press release is available in spanish. Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing Testing
### END ...
Boston (May 7, 2013) – The first successful cornea transplant with donor endothelial tissue preloaded by an eye bank has been performed at Massachusetts Eye and Ear in Boston, Mass. Roberto Pineda II, M.D., Director of the Refractive Surgery Service at Mass. Eye and Ear, and an Associate Professor of Ophthalmology at Harvard Medical School, recently performed the groundbreaking transplant.
Dr. Pineda performed the surgery utilizing donor endothelial tissue that was prepared and pre-loaded into EndoGlide™ (Angiotech Pharmaceuticals, Inc.) cartridges at the Lions Eye Institute ...
WASHINGTON, May 7, 2013 – From New York City's Central Park to Golden Gate Park in San Francisco, America's urban forests store an estimated 708 million tons of carbon, an environmental service with an estimated value of $50 billion, according to a recent U.S. Forest Service study.
Annual net carbon uptake by these trees is estimated at 21 million tons and $1.5 billion in economic benefit.
In the study published recently in the journal Environmental Pollution, Dave Nowak, a research forester with the U.S. Forest Service's Northern Research Station, and his colleagues ...
(PHILADELPHIA) An international group of investigators, led by researchers at Thomas Jefferson University's Kimmel Cancer Center, have solved the mystery of why a substantial percentage of castrate-resistant metastatic prostate cancer cells contain abnormally high levels of the pro-growth protein Stat5. They discovered that the gene that makes the protein is amplified — duplicated many times over — in these cancer cells, which allows them to produce excess amounts of the oncogenic protein.
The study, reported in the May 7 issue of the American Journal of Pathology, found ...
